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Abstract
Objectives: Laparoscopy is recommended to detect radiographically occult metastases in patients with
pancreatic cancer before curative resection. This study was conducted to test the hypothesis that
diagnostic laparoscopy (DL) is cost-effective in patients undergoing curative resection with or without
neoadjuvant therapy (NAT).
Methods: Decision tree modelling compared routine DL with exploratory laparotomy (ExLap) at the time
of curative resection in resectable cancer treated with surgery first, (SF) and borderline resectable cancer
treated with NAT. Costs (US$) from the payer's perspective, quality-adjusted life months (QALMs) and
incremental cost-effectiveness ratios (ICERs) were calculated. Base case estimates and multi-way sen-
sitivity analyses were performed. Willingness to pay (WtP) was US$4166/QALM (or US$50 000/quality-
adjusted life year).
Results: Base case costs were US$34 921 for ExLap and US$33 442 for DL in SF patients, and
US$39 633 for ExLap and US$39 713 for DL in NAT patients. Routine DL is the dominant (preferred)
strategy in both treatment types: it allows for cost reductions of US$10 695/QALM in SF and US$4158/
QALM in NAT patients.
Conclusions: The present analysis supports the cost-effectiveness of routine DL before curative
resection in pancreatic cancer patients treated with either SF or NAT.
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Introduction
Pancreatic cancer (PC) continues to represent a significant health
care challenge.Numbers of new cases and deaths in 2013 in the US
were estimated as 45 220 and 38 460, respectively.1 The economic
impact of the treatment of PC is significant; average treatment
costs per patient range from US$10 400 for treatment with
chemotherapy alone to US$58 200 for surgery and adjuvant
therapy.2
Given the significant economic impact of this disease in a
setting of increasingly limited resources, it is important that treat-
ment strategies be optimized in terms of both patient benefit and
cost-effectiveness. Diagnostic laparoscopy (DL) can identify
patients with radiographically occult metastatic disease that is not
amenable to resection prior to an exploratory laparotomy (ExLap)
and thereby avoid a non-therapeutic laparotomy.3,4 In addition to
avoiding surgery-associated morbidity, laparoscopy may also be
able to facilitate the early initiation of systemic chemotherapy.
Although this directly increases the cost of a procedure, indirect
benefits of DL in terms of economic and human resource gains
can be derived by avoiding an unnecessary ExLap.5 Thus, several
groups have supported DL as the optimal approach before defini-
tive resection.
There are few studies on the cost-effectiveness of routine DL
in patients with localized PC4–8 and none in the context of
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neoadjuvant therapy (NAT). Neoadjuvant therapy can facilitate
the selection of patients with appropriate biology and can also
shrink the tumour and thereby help to reduce positive margin
rates in patients with PC.
The present study tested the hypothesis that DL is cost-effective
in patients with localized PC treated with surgery first (SF), as well
as in those treated with the evolving paradigm of NAT.
Materials and methods
A decision tree was constructed using TreeAgePro 2012
(TreeAgePro, Inc., Williamstown, MA, USA). Two distinct patient
groups were studied: (i) PC patients treated in the SF paradigm,
and (ii) patients with borderline resectable (BR) PC treated with
NAT.
Decision model
The reference case for the model is a PC patient found to be
resectable at restaging evaluation (according to imaging and func-
tional criteria) and selected for definitive resection. The decision
tree compared the two competing strategies of routine DL and
direct ExLap, respectively. Patients who underwent resection sub-
sequently transitioned to recovery with or without complications.
Patients excluded from resection were either submitted to pallia-
tive surgery or given no intervention. A second decision node
selected patients to undergo one of two palliative interventions: (i)
double bypass with gastrojejunostomy and hepaticojejunostomy,
or (ii) gastrojejunostomy with biliary stenting. Complications and
recovery without complications were incorporated downstream.
Patients excluded from resection and those who did not receive
any palliative intervention also transitioned to recovery with or
without complications.
A systematic search was conducted in PubMed to choose the
most accurate probabilities (Table 1). Best assumptions were used
when data were unavailable. Pay-offs at the terminal nodes
included two components: (i) total costs, and (ii) quality-adjusted
life months (QALMs).
The probability of detection of peritoneal metastases and other
anatomic causes of exclusion from resection were extracted from
the literature (Table 1) and analysed separately for: (i) SF patients,
and (ii) BR patients in the NAT setting. In BR patients with PC
undergoing restaging, the probability of unresectability was 0.16
or 16% (0.10 from peritoneal metastases and 0.06 from locally
invasive disease).9 The probability of exclusion from resection in
the SF group was 0.35 or 35% (range: 0.30–0.60).3,10–23 The prob-
ability of palliative intervention was assumed to be 0.10 (range:
0.0–0.40).
The probability of developing complications after non-
therapeutic laparotomy was assumed to be higher than that in DL
(0.25 versus 0.04) (Table 1). Average quality of life (QoL) after
non-therapeutic laparotomy was also adjusted to be lower based
on standardized QoL scales to be described.
Costs
Costs were determined from a third-party payer’s perspective
based on Medicare payments in 2012 (Appendix 1). Medicare’s
national-level relative-value payments for 2012 for various pro-
cedures were obtained using Current Procedural Terminology
(CPT) codes from the American Medical Association’s (AMA)
CPT code-based relative value search.24
Hospital payments were calculated using International Classi-
fication of Diseases, 9th Revision (ICD-9), procedural and
diagnosis-related group (DRG) codes. Data were extracted from
Table 1 Probabilities used for base case estimates and ranges for sensitivity analyses
Variable Neoadjuvant
therapy
Range Surgery
first
Range References
Exclusion from resection
Overall probability for exclusion from resection 0.16 0.10–0.30 0.35 0.30–0.60 3,9–23,28,31,32
Proportion from peritoneal metastases 60% Not varied 40% Not varied 3,9–23,28,31,32
Proportion from locally invasive disease/liver metastases 40% Not varied 60% Not varied 3,9–23,28,31,32
Sensitivity of laparoscopy
Peritoneal metastases 25% 20–60% 90% 85–95% 3,9–23,28,31,32
Locally invasive disease/liver metastases 25% Not varied 80% 75–85% 3,9–23,28,31,32
Palliative intervention if excluded from resection
Probability 0.10 0.0–0.40 0.10 0.0–0.40
Postoperative complications (minor plus major complications)
Diagnostic laparoscopy 0.04 0.01–0.05 0.04 0.01–0.05 4
Exploratory laparotomy 0.25 0.10–0.50 0.25 0.10–0.50 33
Pancreaticoduodenectomy 0.35 0.10–0.50 0.35 0.10–0.50 9,28,34,35
Gastrojejunostomy plus hepaticojejunostomy 0.30 0.10–0.50 0.30 0.10–0.50 36,37
Gastrojejunostomy plus biliary stent 0.25 0.10–0.25 0.25 0.10–0.25 38–40
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the Nationwide Inpatient Sample of the Healthcare Cost and Uti-
lization Project (HCUP) of the Agency for Healthcare Research
and Quality.25 The values available referred to 2010 and were
converted to 2012 US$ using an inflation calculator available from
the Bureau of Labor Statistics website.26 Total charges can be con-
verted to approximate costs using cost-to-charge ratios based on
hospital accounting reports from the Centers for Medicare and
Medicaid Services (CMS) and are available from the HCUP
website.25 Ratios of major and minor complications according to
DRG codes were used to estimate similar costs for CPT codes. If a
patient had undergone a subsequent laparotomy or pancreatic
resection, 50% of CPT charges for laparoscopy and 30 min of
additional anaesthesia time were added. No additional ICD-9
code-based costs were added.
Medicare-based payments for anaesthesia during surgery and
for epidurals were added to the surgical costs after adjusting for
duration (Appendix 2). Separate analyses were performed for
patients who were assumed not to have received an epidural, but
these results are not presented because they were essentially iden-
tical. Payments for ExLap were used for non-therapeutic lapa-
rotomy. Payments for readmission after surgery, treatment of
complications of chemotherapy or radiotherapy, and end-of-life
care were not included in the analysis. No discounting was
required as QALMs were calculated for a 6-month period.
Utility
Average global function QoL data based on the Functional Assess-
ment of Cancer Therapy (FACT) scoring system over 6 months
were obtained for patients treated with resection and those
excluded from resection (Appendix 3). These values were
obtained for patients submitted to palliative interventions, as well
as for those who were not. These data were used to calculate
QALMs for all patients at the end of 6 months. Factors for a
reduction in QoL after the occurrence of complications were esti-
mated from the literature.
Analyses
The incremental cost-effectiveness ratio (ICER) is calculated as
the difference in mean total costs divided by the difference in
mean QALMs for the two strategies and represents the incremen-
tal costs per unit QALM. The general principles of dominance and
extended dominance were used for making conclusions. A
willingness-to-pay (WtP) of US$4166 per QALM, which corre-
sponds to about US$50 000 per quality-adjusted life year (QALY)
was used.2 To explore the uncertainty in the parameter estimates,
extensive one-way, two-way and multi-way sensitivity analyses
were performed on all variables for which assumptions were
made.
Results
Base case estimates
The total costs, average QALMs, incremental costs, incremental
QALMs and ICERs calculated at baseline are shown in Table 2.
In the SF approach, the DL strategy was cheaper (US$33 441
versus US$34 921), yet provided higher QoL (4.35 QALM versus
4.21 QALM), and thus yielded a favourable ICER (US$10 695/
QALM).
In BR cancer, although the cost was marginally higher
(US$39 713 versus US$39 633), the improvement in QALM (4.35
versus 4.33) led to a positive ICER of US$4158/QALM.
From a societal perspective, if the value of one QALY were to
be set at US$50 000 (WtP), the strategy of DL would be
cost-effective.
Sensitivity analyses
Sensitivity analyses were performed to test the internal validity of
the model as well as to identify any factors that altered the favour-
able strategy at base case-level (ExLap). If the proportion of
patients with metastatic disease remained at 30–60%, DL would
be cost-effective at all estimates.
In the NAT setting, if the proportion of patients with
unresectable disease were <16% or if the sensitivity of laparoscopy
were <25%, routine laparoscopy would not be cost-effective.
If the likelihood of performing an open palliative bypass opera-
tion were >10%, the cost-effectiveness of a laparoscopy would be
significantly diminished.
The increase in the preoperative detection of advanced disease
by improved imaging would lead to a reduction in the probability
of advanced disease. This is modelled in Figs 1 and 2 with differing
WtP values.
Table 2 Base case estimates in the different scenarios in pancreatic cancer [surgery first (SF) and borderline resectable (BR)]
Strategy Cost,
US$
Incremental cost,
US$
Effectiveness,
QALMs
Incremental effect,
QALMs
ICER,
US$/QALM
SF
ExLap 34 921 0 4.21 0.00 0
DL 33 442 − 1479 4.35 0.14 − 10 695
BR
ExLap 39 633 0 4.33 0.00 0
DL 39 713 80 4.35 0.02 4158
DL, diagnostic laparoscopy; ExLap, exploratory laparotomy; ICER, incremental cost-effectiveness ratio; QALM, quality-adjusted life months.
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Figure 1 Variation in the cost-effectiveness of diagnostic laparoscopy in pancreatic cancer with probability for advanced disease and
sensitivity of laparoscopy. (Willingness to pay US$50 000/quality-adjusted life year.) SF, surgery first paradigm; NAT, neoadjuvant therapy
paradigm in borderline resectable pancreatic cancer
Figure 2 Variation in the cost-effectiveness of diagnostic laparoscopy in pancreatic cancer with probability for advanced disease and
sensitivity of laparoscopy. (Willingness to pay US$100 000/quality-adjusted life year.) SF, surgery first paradigm; NAT, neoadjuvant therapy
paradigm in borderline resectable pancreatic cancer
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Discussion
The present model demonstrates the cost-effectiveness of routine
laparoscopy before definitive resection in patients with PC, either
with or without NAT. The high probability of advanced disease
undetected by imaging, and the burden of a non-therapeutic lapa-
rotomy were the main factors that altered costs in this model.
Better preoperative detection of metastases (which reduces the
presentation of advanced disease), decreased sensitivity of lapa-
roscopy and an increase in the proportion of patients offered a
palliative bypass would make a routine DL less cost-effective.
Balancing the expenses associated with the care of patients with
cancer with the need to achieve the optimal use of limited
resources has become a societal issue and, although it is impos-
sible to assign a cost value to a human life, physicians are often
charged with the responsibility of allocating scarce resources. The
incorporation of an expensive technological procedure such as
laparoscopy during a planned definitive resection would intui-
tively appear to add to both costs and time in the operating room.
However, what cannot intuitively be measured is the additional
morbidity associated with laparotomy, the utilization of resources
and the emotional burden imposed on the patient before his or
her return to chemotherapy. The present model represents a
modest attempt to make such an estimation.
In the present study, both the SF and the NAT approaches were
modelled because although the SF approach has been the conven-
tional strategy, the evolving paradigm of NAT has led to improved
patient outcomes and is also cost-effective.
The average cost of NAT is estimated to be lower than that of
an SF approach (US$36 580 and US$46 830, respectively).
Neoadjuvant therapy was also found to be more effective in terms
of QALMs (18.8 QALMs versus 8.7 QALMs).27
There are special considerations in patients submitted to DL
after NAT. Firstly, inherent to NAT is the exclusion of patients with
advanced disease, which means that the probability of finding
abnormalities on laparoscopy is lower.9,28,29 Secondly, the sensitiv-
ity of DL to detect metastases has been fairly low in phase II
clinical trials of NAT.28 Despite suboptimal diagnostic test charac-
teristics in this situation,DL remained cost-effective in the present
model for patients with BR disease. The WtP value of US$4166/
QALM used in this model is directly converted from a value of
US$50 000/QALY.2,27 This is universally accepted, but may change
according to societal and economic conditions. In patients with
resectable disease who are treated with NAT, the probability of
peritoneal metastases is extremely low (4%) and, according to the
current model, routine laparoscopy may not be cost-effective.
However, no specific model was built for this.
Although the cost differential between the two groups is not
dramatic, the slight increase in QoL favours a laparoscopy-first
approach. Numerous studies have demonstrated equivalent QoL
after laparotomy and DL at 6 weeks after the procedure in benign
conditions, although a larger incision is associated with higher
short-term morbidity. Additionally, this could delay the initiation
of systemic chemotherapy, which may be clinically signifi-
cant.4,5,11,30 Although the present study was unable to capture this
effect of delay in the receipt of systemic therapy, a better under-
standing of this issue might alter the WtP (US$50 000/QALY)
from both a payer and a societal perspective, thereby making a
stronger case for the cost-effectiveness of DL and other strategies
to avoid non-therapeutic interventions (Figs 1 and 2).
For the sake of simplicity and in order to utilize available prob-
abilities, in the present study a decision analysis model was
chosen, rather than a semi-probabilistic model such as a Markov
model or neural network analysis. The model uses some assump-
tions based on best case estimates, yet fallacies may occur.
There are certain clinical nuances that cannot be estimated in
the present work. For instance, changes in the functional status of
patients after NAT or changes in the appearance of the tumour
may preclude surgical resection. Although this is not modelled
separately, the effect estimates of patients obtained from phase II
clinical trials are expected to capture this variability.
The routine use of DL may require the consideration of factors
other than cost. Process improvement demands efficiency and the
use and set-up of laparoscopic equipment for a short duration
before a casemight impair process flow and throughput, and incur
the utilization of additional human resources. This may lead sur-
geons to apply clinical characteristics such as carbohydrate antigen
(CA) 19-9 levels and tumour size to dictate the sparing use of
laparoscopy. Enriching strategies with selective laparoscopy would
certainly be better than definitive laparotomies in all patients. The
increased use of such equipment in low-resource situations and the
greaterwear and tear imposedon itmay contribute to both increas-
ing costs and the inability to use such technology in contexts in
which it is more useful. Because it uses a payer perspective, the
present model does not capture the nuances of individual costs,
such as those of operating room time or the equipment used.
However, this approach makes the model more uniformly appli-
cable across institutions. Themodel does not capture the costs of a
purely minimally invasive pancreaticoduodenectomy and the
additional cost of DL. Although this is an emerging technology, it
has not yet been widely adopted and therefore was not included in
the cost modelling.
Conclusions
At present, it is cost-effective to perform DL prior to resection in
patients with localized PC. In the future, as imaging modalities
become more accurate, this strategy may become less cost-
effective.
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Appendix 1
Estimates for professional and hospital reimbursement based on Medicare data
CPT
code
CPT
payment,
US$
DRG
code
DRG
cost,
US$a
DRG
cost
ratiob
ICD-9
code
ICD-9
payment,
US$c
Total
procedure
cost, US$d
Resection
Pancreaticoduodenectomy without complications 48150 3071 407 15 602 52.7 32 708 35 779
Minor complications 48150 3071 406 20 315 1.30 52.7 42 589 45 660
Major complications 48150 3071 405 33 199 2.13 52.7 69 599 72 670
Diagnostic procedures
Diagnostic laparoscopy without complications 49320 326 437 6635 54.21 10 716 11 042
Minor complications 49320 326 436 7555 1.14 54.21 12 202 12 528
Major complications 49320 326 435 10 589 1.60 54.21 17 102 17 428
Exploratory laparotomy without complications 49000 766 437 4780 54.1 15 530 16 296
Minor complications 49000 766 436 5385 1.13 54.1 17 496 18 262
Major complications 49000 766 435 8683 1.82 54.1 28 212 28 978
Palliative surgeries
Gastrojejunostomy without complications 43820 1346 390 4363 44.3 13 525 14 871
Minor complications 43820 1346 389 5606 1.28 44.3 17 378 18 724
Major complications 43820 1346 388 7930 1.82 44.3 24 581 25 927
Hepaticojejunostomy without complications 47780 2476 410 12 638 51.37 24 832 27 308
Minor complications 47780 2476 409 16 599 1.31 51.37 32 615 35 091
Major complications 47780 2476 408 24 583 1.95 51.37 48 302 50 778
Gastrojejunostomy plus hepaticojejunostomy
without complicationse
34 744
Minor complications 44 453
Major complications 63 742
Palliative endoscopic intervention
Duodenal stent without complications 43268 257 390 4363 44.22 7346 7603
Minor complications 43268 257 389 5606 1.28 44.22 9439 9696
Major complications 43256 257 388 7930 1.82 44.22 13 352 13 609
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CPT
code
CPT
payment,
US$
DRG
code
DRG
cost,
US$a
DRG
cost
ratiob
ICD-9
code
ICD-9
payment,
US$c
Total
procedure
cost, US$d
Biliary stent without complications 43268 438 410 12 638 51.87 11 116 11 554
Minor complications 43268 438 409 16 599 1.31 51.87 14 600 15 038
Major complications 43268 438 408 24 583 1.95 51.87 21 623 22 061
Anaesthesia
Anaesthesia, per min 794 2 2
Anaesthesia, epidural 64483 115 240
aCosts tend to reflect the actual costs of production, whereas charges represent what the hospital was billed for the case. Total charges were converted to costs
using cost-to-charge ratios based on hospital accounting reports from the Centers for Medicare and Medicaid Services (CMS) and are available from the
HCUP website.25
bRatio of DRG-based costs for procedures with complications (minor or major) to payments for procedures without complications.
cFor minor and major complications, ICD-9-based values for the procedures were multiplied by ratios calculated from DRG-based costs as described above.
dTotal cost is calculated as the sum of technical and procedural fees (CPT-based) and hospital payment (ICD-9-based).
eCalculated as the sum of the total cost of hepaticojejunostomy and 50% of the total cost of gastrojejunostomy (modifier 51).
CPT, Current Procedural Terminology; DRG, disease-related group; ICD-9, International Classification of Diseases, 9th Revision.
Appendix 2
Utility according to quality-adjusted life months (QALMs) calculated using average global function quality of life (GF-QoL) scores over 6
months based on the Functional Assessment of Cancer Therapy (FACT) scoring system
GF-QoL QALMsa References
Patients undergoing Whipple procedures (pancreaticoduodenectomy)
Surgery with no complications 78.30 4.70 41
Minor complications 70.47 4.23
Major complications 54.81 3.29
Patients excluded from resection and any palliative intervention
Only laparoscopy with no complications 71.30 4.28 41,42
Minor complications 64.17 3.85
Major complications 49.91 2.99
Non-therapeutic laparotomy with no complications 64.17 3.85 41,42
Minor complications 57.75 3.47
Major complications 44.92 2.70
Patients excluded from resection and receiving palliative double bypass
No complications 72.80 4.37 41
Minor complications 65.52 3.93
Major complications 50.96 3.06
Patients undergoing palliative gastrojejunostomy with biliary stent
No complications 74.15 4.45 41
Minor complications 66.74 4.00
Major complications 51.91 3.11
aQALM values were obtained by multiplying (GF-QoL/100) by 6 (horizon for the study: 6 months).
Appendix 3
Calculations used for deriving probabilities: (i) quality of life (QoL) modifier for diagnostic laparoscopy versus diagnostic laparotomy,
and (ii) QoL modifier for patients developing minor and major complications.
Average QoL over 6 months = (QoL at 1 month + QoL at 6 months)/2
QoL modifier for diagnostic laparoscopy versus diagnostic laparotomy
[From a study in patients undergoing staging for endometrial cancer (Kornblith et al.42)]
Average QoL over 6 months after diagnostic laparotomy = 81.5
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Average QoL over 6 months after diagnostic laparoscopy = 84.5
Ratio of these two values = 0.96
Thus the model assumed:
Average QoL over 6 months after diagnostic laparoscopy and no palliative interventions = (average QoL over 6 months for patients
who did not undergo resection and received no palliative intervention as obtained from the literature)
Based on this calculation and assuming a conservative approach favouring laparoscopy:
Average QoL over 6 months after diagnostic laparotomy and no palliative interventions = 0.9* (average QoL over 6 months after
diagnostic laparoscopy and no palliative interventions)
QoL modifier for patients developing minor and major complications
[Based on results from a study in patients undergoing oesophageal resection for cancer (Rutegard et al.43)]
Ratio of (QoL over 6 months with perioperative complications) to (QoL without complications) = 0.8
For the model, this ratio was assumed to be 0.9 for minor complications (modifier for minor complications) and 0.7 for major
complications (modifier for major complications).
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